Miscellaneous treatments for antipsychotic-induced tardive dyskinesia

Soares‐Weiser, Karla; Rathbone, John; Ogawa, Yoshihide; Shinohara, Kiyomi

doi:10.1002/14651858.cd000208.pub2

Cited by 16 publications

(15 citation statements)

References 130 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on the rule of thumb that it requires 3 to 5 elimination half-lives to eliminate a drug from the body, some paliperidone could still be present after 14 months. 3,4,[13][14][15] After decreasing the dose of olanzapine from 10 to 5 mg, the blepharospasms increased. After further reduction to 2.5 mg, the blepharospasms increased even further.…”

Section: Discussionmentioning

confidence: 99%

Case Report

Heikens

Beex-Oosterhuis

2022

J Clin Psychopharmacol

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Case Report

Heikens

Beex-Oosterhuis

2022

J Clin Psychopharmacol

View full text Add to dashboard Cite

“…Numerous and mostly flawed past clinical trials of agents engaging diverse pharmacological targets yielded inconclusive or negative results. 141,143,[157][158][159] In contrast, recent trials have provided robust evidence on the efficacy and tolerability of valbenazine and deutetrabenazine (Table 4). Like tetrabenazine, these drugs act to deplete dopamine and thereby reduce the severity of TD by inhibiting VMAT2 in nerve terminals, which ordinarily protects dopamine from the metabolic breakdown by transporting monoamines into protective vesicles.…”

Section: Formulating Individualized Treatment Plans For Patients With...mentioning

confidence: 99%

A new era in the diagnosis and treatment of tardive dyskinesia

Caroff

2022

CNS Spectr.

View full text Add to dashboard Cite

Tardive dyskinesia (TD) is a heterogeneous, hyperkinetic movement disorder induced by dopamine-receptor blocking agents that presents a unique challenge in the treatment of psychosis. Although acceptance of TD as a serious consequence of antipsychotic treatment was resisted initially, subsequent research by many investigators in psychopharmacology contributed to a rich store of knowledge on many aspects of the disorder. While basic neuroscience investigations continue to deepen our understanding of underlying motor circuitry, past trials of potential treatments of TD focusing on a range of theoretical targets were often inconclusive. Development of newer antipsychotics promised to reduce the risk of TD compared to older drugs, but their improved tolerability unexpectedly enabled an expanding market that paradoxically both increased the absolute number of patients at risk and diminished attention to TD which was relegated to legacy status. Fortunately, development and approval of novel vesicular monoamine transporter inhibitors offered evidence-based symptomatic treatment of TD for the first time and rekindled interest in the disorder. Despite recent progress, many questions remain for future research including the mechanisms underlying TD, genetic predisposition, phenomenological diversity, whether new cases are reversible, how to implement best practices to prevent and treat TD, and whether the development of novel antipsychotics free of the risk of TD is attainable. We owe our patients the aspirational goal of striving for zero prevalence of persistent symptoms of TD in anyone treated for psychosis.

show abstract

“…The record of clinical trials of agents to treat TD is extensive. Virtually all reviews and meta-analyses of these trials have concluded that the evidence on effectiveness for most of these agents remains preliminary and inconclusive 75,86,98,99. However, these reviews have been of limited usefulness to clinicians because they focus on trial design and statistical validity but less so on tolerability, reliability, and availability of products, while antipsychotics and anticholinergics are analyzed equally with specific antidyskinetics, apart from their psychiatric necessity.…”

Section: Treatment Of Tdmentioning

confidence: 99%

<p>Overcoming barriers to effective management of tardive dyskinesia</p>

Caroff¹

2019

NDT

View full text Add to dashboard Cite

Tardive dyskinesia (TD) is a heterogeneous syndrome of involuntary hyperkinetic movements that is often persistent and occurs belatedly during treatment with antipsychotics. Recent approval of two dopamine-depleting analogs of tetrabenazine based on randomized controlled trials offers an evidence-based therapeutic approach to TD for the first time. These agents are optimally used within the context of a comprehensive approach to patient management that includes a practical screening and monitoring program, sensitive and specific criteria for the diagnosis of TD, awareness of the severity and impact of the disorder, informed discussions with patients and caregivers, and a rational basis for prescribing decisions about continued antipsychotic and adjunctive agents. Areas of limited or inconclusive data, bias and misunderstandings about key aspects, and neglect of training about TD in recent years contribute to barriers in providing effective care and promoting patient safety.

show abstract

Miscellaneous treatments for antipsychotic-induced tardive dyskinesia

Abstract: Miscellaneous treatments for antipsychotic-induced tardive dyskinesia.

Cited by 16 publications

References 130 publications

Case Report

Case Report

A new era in the diagnosis and treatment of tardive dyskinesia

<p>Overcoming barriers to effective management of tardive dyskinesia</p>

Contact Info

Product

Resources

About